CYP2D6*4 polymorphism is associated with statin-induced muscle effects

被引:60
作者
Frudakis, Tony N. [1 ]
Thomas, Matthew J. [1 ]
Ginjupalli, Siva N. [1 ]
Handelin, Barbara [1 ]
Gabriel, Richard [1 ]
Gomez, Hector J. [1 ]
机构
[1] DNAPrint Genom Inc, Sarasota, FL 34236 USA
关键词
adverse event; atorvastatin; CYP2D6; CYP2D6*4; hypercholesterolemia; muscle; myalgia; pharmacogenetics; polymorphism; rhabdomyolysis; statins;
D O I
10.1097/FPC.0b013e328012d0a9
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Statin use is associated with a variety of overtly related muscle symptoms including muscle pain, myalgia, creatine kinase elevations without pain with myolysis and myositis (rhabdomyolysis), a potentially fatal side effect that led to the withdrawal of cerivastatin in 2001. Unintended drug response phenotypes have an impact on patient compliance and sometimes patient health and the assessment of risk on an individual basis could enhance therapeutic benefit. We therefore investigated whether common single nucleotide polymorphisms were associated with the expression of broadly grouped atorvastatin-induced muscle events in a case-control study (n=263 samples, n=388 SNPs). Of a number of associations identified in a discovery sample (51 atorvastatin-incluced muscle and 55 normal) only those corresponding to the CYP2D6*4 allele were significantly associated in the sample (24 atorvastatin-induced muscle and 133 normal) (Discovery P=0.004, odds ratio=3.6; Validation P= 0.036, odds ratio = 2.7; total P= 0.001, odds ratio= 2.5). The frequency of the CYP2D6*4 allele was about 50% in atorvastatin-induced muscle patients but only 28% in controls, similar to that of other patient types (28.5%). The association was independent of various demographic variables and not explained by gross demographic, clinical or population-structure differences among cases and controls. Surprisingly, the CYP2D6*4 allele appeared similarly distributed among controls and patients expressing simivastatin-incluced muscle events (n = 169, frequency in case participants = 49.2%, P=0.067, odds ratio= 1.7). Our results suggest that the CYP2D6*4 allele is associated with broadly related muscle events caused by at least two structurally dissimilar HMG-CoA reductase inhibitors, and as such, may have implications for a better understanding of this statin-wide phenomena. Pharmacogenetics and Genomics 17:695-707 (c) 2007 Lippincott Williams & Wilkins.
引用
收藏
页码:695 / 707
页数:13
相关论文
共 71 条
[1]  
BERNSTEIN F, COMITATO ITALIANO ST, P227
[2]   LONG-TERM SAFETY AND EFFICACY PROFILE OF SIMVASTATIN [J].
BOCCUZZI, SJ ;
BOCANEGRA, TS ;
WALKER, JF ;
SHAPIRO, DR ;
KEEGAN, ME .
AMERICAN JOURNAL OF CARDIOLOGY, 1991, 68 (11) :1127-1131
[3]   Admixture in the Hispanics of the San Luis Valley, Colorado, and its implications for complex trait gene mapping [J].
Bonilla, C ;
Parra, EJ ;
Pfaff, CL ;
Dios, S ;
Marshall, JA ;
Hamman, RF ;
Ferrell, RE ;
Hoggart, CL ;
McKeigue, PM ;
Shriver, MD .
ANNALS OF HUMAN GENETICS, 2004, 68 :139-153
[4]   CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants [J].
Bradford, LD .
PHARMACOGENOMICS, 2002, 3 (02) :229-243
[5]   Polymorphisms of the CYP2D6 gene increase susceptibility to ankylosing spondylitis [J].
Brown, MA ;
Edwards, S ;
Hoyle, E ;
Campbell, S ;
Laval, S ;
Daly, AK ;
Pile, KD ;
Calin, A ;
Ebringer, A ;
Weeks, DE ;
Wordsworth, BP .
HUMAN MOLECULAR GENETICS, 2000, 9 (11) :1563-1566
[6]  
CHAKRABORTY R, 1986, YEARB PHYS ANTHROPOL, V29, P1
[7]   Population stratification confounds genetic association studies among Latinos [J].
Choudhry, S ;
Coyle, NE ;
Tang, H ;
Salari, K ;
Lind, D ;
Clark, SL ;
Tsai, HJ ;
Naqvi, M ;
Phong, A ;
Ung, N ;
Matallana, H ;
Avila, PC ;
Casal, J ;
Torres, A ;
Nazario, S ;
Castro, R ;
Battle, NC ;
Perez-Stable, EJ ;
Kwok, PY ;
Sheppard, D ;
Shriver, MD ;
Rodriguez-Cintron, W ;
Risch, N ;
Ziv, E ;
Burchard, EG .
HUMAN GENETICS, 2006, 118 (05) :652-664
[8]   RHABDOMYOLYSIS DUE TO COMBINED TREATMENT WITH LOVASTATIN AND CHOLESTYRAMINE [J].
CHRYSANTHOPOULOS, C ;
KOUNIS, N .
BRITISH MEDICAL JOURNAL, 1992, 304 (6836) :1225-1225
[9]   Equally potent inhibitors of cholesterol synthesis in human hepatocytes have distinguishable effects on different cytochrome P450 enzymes [J].
Cohen, LH ;
van Leeuwen, REW ;
van Thiel, GCF ;
van Pelt, JF ;
Yap, SH .
BIOPHARMACEUTICS & DRUG DISPOSITION, 2000, 21 (09) :353-364
[10]  
Collins R, 2002, LANCET, V360, P7, DOI 10.1016/S0140-6736(02)09327-3